"Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3

Épisode de Pharma Minds par Nathalie Lahitte · 28 septembre 2026 · 31 min

What happens to pharmaceutical innovation when your competitive window shrinks from eight years to just three?

In this episode of Pharma minds, I speak with Marine Baxendell, CFO and co-fonder at xcube.bio, about a fundamental shift in the economics of pharma innovation.

Science is moving faster. Competition is accelerating. And at the same time, MFN pricing, healthcare budget pressures and increasingly complex market access are challenging the traditional model on both sides of the Atlantic.

An innovative treatment could once expect five to eight years before serious competition entered the same space. Today, Marine argues, that window can be closer to two or three years, even while the original molecule remains protected.

So what happens when the time available to capture the value of innovation gets shorter?

We explore:

◾️ Why the next wave of pharma innovation is structurally different

◾️ What MFN reveals about the limits of today’s pricing model

◾️ Why demonstrating patient value earlier is becoming critical

◾️ What is really slowing market access in Europe

◾️ Why being first to market may no longer be enough

◾️ And what a more sustainable model for pharma, payers and patients could look like

Marine’s perspective reframes MFN not simply as a threat, but as a signal that the rules of pharmaceutical innovation are changing.

This is episode #4 of Europe’s Access Dilemma: five perspectives on how Europe can make innovation affordable.

To find Marine Baxendell:

LinkedIn: https://www.linkedin.com/in/marine-baxendell/

Resources mentioned in the episode:

📌 xcube.bio : https://xcube.bio/

___

📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Autres épisodes de « Pharma Minds »

• #53 - Libérer du temps soignant : le pari d'un ingénieur à la Clinique Pasteur 19 octobre 2026
• [EXTRAIT] « On a toujours fait comme ça » : comment faire accepter le changement ? avec Loïc Lagarde 18 octobre 2026
• "Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced 12 octobre 2026
• "Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up? 5 octobre 2026
• "Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare. 21 septembre 2026
• "Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia 14 septembre 2026
• "Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why. 7 septembre 2026
• [Insights] Produits frontières : transformer la réglementation en avantage stratégique 2 septembre 2026
• "Executing differently takes courage" (5/5) - From managing global subsidiaries to walking the talk : when execution becomes personal 17 août 2026
• "Executing differently takes courage" (4/5) - Biotech survival and resource allocation : why execution is about choosing what not to do 10 août 2026
• "Executing differently takes courage" (3/5) - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone 3 août 2026
• "Executing differently takes courage" (2/5) - The Chinese pharma ecosystem : balancing systemic scale and constant reinvention 27 juillet 2026
• "Executing differently takes courage" (1/5) Transforming Vidal : how a 20-year vision turned a paper book into digital infrastructure 20 juillet 2026
• [Insights] Groupements de pharmacies : ce qu’il faut retenir du rapport IGF-IGAS, avec Hugues Villey Desmeserets 8 juillet 2026
• #52 - Prévention santé : le courage d'investir sans en récolter les fruits soi-même, avec Anne Beinier 22 juin 2026

Tous les épisodes de Pharma Minds · Plus de podcasts Business